Gene name:
MAP2K1 (MEK1;PRKMK1) ;
Protein name:
Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1;MAPKK 1;MKK1) ;
Alternative:
MAPK/ERK kinase 1 (MEK 1) ;ERK activator kinase 1 ;
Organism:
Human (Homo sapiens).
General Annotation
Sub Unit:
Interacts with MORG1. Interacts with ARRB2. Found in a complex with at least BRAF, HRAS1, MAP2K1, MAPK3 and RGS14 (By similarity). Interacts with Yersinia yopJ. Interacts with isoform 1 of VRK2.
Function:
Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
Subcellular Location:
N/A
Protein Attributes:
50:
MPKKKPTPIQ | LNPAPDGSAV | NGTSSAETNL | EALQKKLEEL | ELDEQQRKRL |
100:
EAFLTQKQKV | GELKDDDFEK | ISELGAGNGG | VVFKVSHKPS | GLVMARKLIH |
150:
LEIKPAIRNQ | IIRELQVLHE | CNSPYIVGFY | GAFYSDGEIS | ICMEHMDGGS |
200:
LDQVLKKAGR | IPEQILGKVS | IAVIKGLTYL | REKHKIMHRD | VKPSNILVNS |
250:
RGEIKLCDFG | VSGQLIDSMA | NSFVGTRSYM | SPERLQGTHY | SVQSDIWSMG |
300:
LSLVEMAVGR | YPIPPPDAKE | LELMFGCQVE | GDAAETPPRP | RTPGRPLSSY |
350:
GMDSRPPMAI | FELLDYIVNE | PPPKLPSGVF | SLEFQDFVNK | CLIKNPAERA |
393:
DLKQLMVHAF | IKRSDAEEVD | FAGWLCSTIG | LNQPSTPTHA | AGV
Vaild Sequence:
Related Databases
Uniprot:
ELISA Kit
CLIA Kit
Polyclonal Antibody
Monoclonal Antibody
Protein
FOR
Human
Mouse
Rat
Rabbit
ELISA Kit for Human MAP kinase kinase 1
ELISA Kit for Human MAP kinase kinase 1
ELISA Kit for Human MAP kinase kinase 1
ELISA Kit for Human MAP kinase kinase 1
CLIA Kit for Human MAP kinase kinase 1
CLIA Kit for Human MAP kinase kinase 1
CLIA Kit for Human MAP kinase kinase 1
CLIA Kit for Human MAP kinase kinase 1
Polyclonal Antibody for Human MAP kinase kinase 1
Polyclonal Antibody for Human MAP kinase kinase 1
Polyclonal Antibody for Human MAP kinase kinase 1
Polyclonal Antibody for Human MAP kinase kinase 1
Monoclonal Antibody for Human MAP kinase kinase 1
Monoclonal Antibody for Human MAP kinase kinase 1
Monoclonal Antibody for Human MAP kinase kinase 1
Monoclonal Antibody for Human MAP kinase kinase 1
Protein for Human MAP kinase kinase 1
Protein for Human MAP kinase kinase 1
Protein for Human MAP kinase kinase 1
Protein for Human MAP kinase kinase 1
R&D Technical Data
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
Precision
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
Recovery
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
Linearity
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
References
1.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2);PARTIAL PROTEIN SEQUENCE;TISSUE SPECIFICITY
tissue :
T-cell .
2.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)
3.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : PHOSPHORYLATION AT SER-218 AND SER-222;MUTAGENESIS
4.
"Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor."
Duesbery N.S.
,
Webb C.P.
,
Leppla S.H.
,
Gordon V.M.
,
Klimpel K.R.
,
Copeland T.D.
,
Ahn N.G.
,
Oskarsson M.K.
,
Fukasawa K.
,
Paull K.D.
,
Vande Woude G.F.
Science280:734-737(1998)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : CLEAVAGE BY ANTHRAX LETHAL FACTOR;PROTEIN SEQUENCE OF 9-17
5.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : CLEAVAGE BY ANTHRAX LETHAL FACTOR
6.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : SUBCELLULAR LOCATION;FUNCTION
7.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : PHOSPHORYLATION AT SER-298
8.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : INTERACTION WITH YOPJ;ACETYLATION
9.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : FUNCTION;SUBCELLULAR LOCATION;INTERACTION WITH PPARG
10.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : INTERACTION WITH BIRC6/BRUCE
11.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-286;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
tissue :
Cervix carcinoma .
12.
"Protein kinase SGK1 enhances MEK/ERK complex formation through the phosphorylation of ERK2: implication for the positive regulatory role of SGK1 on the ERK function during liver regeneration."
Won M.
,
Park K.A.
,
Byun H.S.
,
Kim Y.R.
,
Choi B.L.
,
Hong J.H.
,
Park J.
,
Seok J.H.
,
Lee Y.H.
,
Cho C.H.
,
Song I.S.
,
Kim Y.K.
,
Shen H.M.
,
Hur G.M.
J. Hepatol.51:67-76(2009)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : INTERACTION WITH SGK1
13.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
14.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : INTERACTION WITH VRK2
15.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : REVIEW ON FUNCTION
16.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : REVIEW ON ENZYME REGULATION
17.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : REVIEW ON FUNCTION
18.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
19.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : REVIEW ON FUNCTION
20.
"Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition."
Ohren J.F.
,
Chen H.
,
Pavlovsky A.
,
Whitehead C.
,
Zhang E.
,
Kuffa P.
,
Yan C.
,
McConnell P.
,
Spessard C.
,
Banotai C.
,
Mueller W.T.
,
Delaney A.
,
Omer C.
,
Sebolt-Leopold J.
,
Dudley D.T.
,
Leung I.K.
,
Flamme C.
,
Warmus J.
,
Kaufman M.
,
Barrett S.
,
Tecle H.
,
Hasemann C.A.
more...
Nat. Struct. Mol. Biol.11:1192-1197(2004)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 62-392 IN COMPLEX WITH ATP AND INHIBITOR
21.
"4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase."
Spicer J.A.
,
Rewcastle G.W.
,
Kaufman M.D.
,
Black S.L.
,
Plummer M.S.
,
Denny W.A.
,
Quin J. III
,
Shahripour A.B.
,
Barrett S.D.
,
Whitehead C.E.
,
Milbank J.B.
,
Ohren J.F.
,
Gowan R.C.
,
Omer C.
,
Camp H.S.
,
Esmaeil N.
,
Moore K.
,
Sebolt-Leopold J.S.
,
Pryzbranowski S.
,
Merriman R.L.
,
Ortwine D.F.
,
Warmus J.S.
,
Flamme C.M.
,
Pavlovsky A.G.
,
Tecle H.
more...
J. Med. Chem.50:5090-5102(2007)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 62-393 IN COMPLEX WITH ATP AND INHIBITOR
22.
"2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)."
Warmus J.S.
,
Flamme C.
,
Zhang L.Y.
,
Barrett S.
,
Bridges A.
,
Chen H.
,
Gowan R.
,
Kaufman M.
,
Sebolt-Leopold J.
,
Leopold W.
,
Merriman R.
,
Ohren J.
,
Pavlovsky A.
,
Przybranowski S.
,
Tecle H.
,
Valik H.
,
Whitehead C.
,
Zhang E.
Bioorg. Med. Chem. Lett.18:6171-6174(2008)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : X-RAY CRYSTALLOGRAPHY (2.62 ANGSTROMS) OF 62-393 IN COMPLEX WITH ATP AND INHIBITOR
23.
"Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors."
Fischmann T.O.
,
Smith C.K.
,
Mayhood T.W.
,
Myers J.E.
,
Reichert P.
,
Mannarino A.
,
Carr D.
,
Zhu H.
,
Wong J.
,
Yang R.S.
,
Le H.V.
,
Madison V.S.
Biochemistry48:2661-2674(2009)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 35-393 IN COMPLEX WITH ADP AND INHIBITOR
24.
"Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?"
Tecle H.
,
Shao J.
,
Li Y.
,
Kothe M.
,
Kazmirski S.
,
Penzotti J.
,
Ding Y.H.
,
Ohren J.
,
Moshinsky D.
,
Coli R.
,
Jhawar N.
,
Bora E.
,
Jacques-O'Hagan S.
,
Wu J.
Bioorg. Med. Chem. Lett.19:226-229(2009)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 62-382 IN COMPLEX WITH ATP AND INHIBITOR
25.
"RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer."
Iverson C.
,
Larson G.
,
Lai C.
,
Yeh L.T.
,
Dadson C.
,
Weingarten P.
,
Appleby T.
,
Vo T.
,
Maderna A.
,
Vernier J.M.
,
Hamatake R.
,
Miner J.N.
,
Quart B.
Cancer Res.69:6839-6847(2009)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 62-393 IN COMPLEX WITH ATP AND INHIBITOR
26.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 62-382 IN COMPLEX WITH ADP AND INHIBITOR
27.
"Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer."
Dong Q.
,
Dougan D.R.
,
Gong X.
,
Halkowycz P.
,
Jin B.
,
Kanouni T.
,
O'Connell S.M.
,
Scorah N.
,
Shi L.
,
Wallace M.B.
,
Zhou F.
Bioorg. Med. Chem. Lett.21:1315-1319(2011)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 62-382 IN COMPLEX WITH ATP AND INHIBITOR
28.
"Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent."
Isshiki Y.
,
Kohchi Y.
,
Iikura H.
,
Matsubara Y.
,
Asoh K.
,
Murata T.
,
Kohchi M.
,
Mizuguchi E.
,
Tsujii S.
,
Hattori K.
,
Miura T.
,
Yoshimura Y.
,
Aida S.
,
Miwa M.
,
Saitoh R.
,
Murao N.
,
Okabe H.
,
Belunis C.
,
Janson C.
,
Lukacs C.
,
Schuck V.
,
Shimma N.
more...
Bioorg. Med. Chem. Lett.21:1795-1801(2011)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 62-393
29.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : VARIANTS CFC3 SER-53 AND CYS-130
30.
"Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome."
Schulz A.L.
,
Albrecht B.
,
Arici C.
,
van der Burgt I.
,
Buske A.
,
Gillessen-Kaesbach G.
,
Heller R.
,
Horn D.
,
Hubner C.A.
,
Korenke G.C.
,
Konig R.
,
Kress W.
,
Kruger G.
,
Meinecke P.
,
Mucke J.
,
Plecko B.
,
Rossier E.
,
Schinzel A.
,
Schulze A.
,
Seemanova E.
,
Seidel H.
,
Spranger S.
,
Tuysuz B.
,
Uhrig S.
,
Wieczorek D.
,
Kutsche K.
,
Zenker M.
more...
Clin. Genet.73:62-70(2008)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : VARIANT CFC3 VAL-128